Menu
sharewise is moving On the weekend of 22/23 August the new sharewise becomes the main site. Have a look now and tell us what you miss. Go to the new sharewise What changes
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
?

?

0.000%
-
0.000%
-
 
08:10 / Frankfurt WKN: A0B6V4 / Symbol: CCDPF / Name: Canaccord / Stock / Investment Banking & Investment Services / Micro Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Canaccord Financial Inc. Stock

There is no change in the price for Canaccord Financial Inc. today.

Pros and Cons of Canaccord Financial Inc. in the next few years

Pros
?
M***** P*******
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
Cons
?
S********** s********
?
C******** o* t** e**********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Canaccord Financial Inc. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Canaccord Financial Inc. 0.000% 2.907% -3.804% 45.082% 31.111% 55.263% -9.231%
Gensource Potash Corp. 2.310% 2.439% 6.780% 51.807% 96.875% -4.545% -
Fiera Capital Corp. 0.000% 4.412% -10.692% -31.731% -24.064% -36.036% -59.716%
Aberdeen International Inc. 0.000% 100.000% -20.000% -80.000% -14.286% -72.727% -95.385%

News

Tenaya Therapeutics Eyes Q4 Updates for Cardiac Gene Therapies, TN-301Photo, wide shot, wide-angle lens,  Private equity firm, sunset photo at golden hour, photo by Thomas Heaton: https://img.theapi.app/temp/6a5872d8-cc25-46f8-b436-bf3db1953908.png
Tenaya Therapeutics Eyes Q4 Updates for Cardiac Gene Therapies, TN-301

Key Points

Sagimet Biosciences Eyes U.S. Phase III Acne Study After Positive China DataPhoto, wide shot, wide-angle lens,  Hedge fund, neutral atmosphere, photo by Charlie Waite: https://img.theapi.app/temp/95282efd-f725-49c0-be40-aa74627f7ccc.png
Sagimet Biosciences Eyes U.S. Phase III Acne Study After Positive China Data

Key Points

Repay Eyes Faster Growth, Debt Reduction as KUBRA Builds Consumer Billing PlatformPhoto, wide shot, wide-angle lens,  Bank, sunset photo at golden hour, photo by Art Wolfe: https://img.theapi.app/temp/3aa597ca-f944-4a9b-bf8d-3071f3b5a5c9.png
Repay Eyes Faster Growth, Debt Reduction as KUBRA Builds Consumer Billing Platform

Key Points